{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:30Z","timestamp":1760909250297,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objective: To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types. Methods: Consistent with the Program in Evidence-based Program\u2019s standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers. Results: We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III\u2013IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible.<\/jats:p>","DOI":"10.3390\/curroncol28020107","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T22:02:20Z","timestamp":1614636140000},"page":"1114-1124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma"],"prefix":"10.3390","volume":"28","author":[{"given":"Hal","family":"Hirte","sequence":"first","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1A1, Canada"},{"name":"Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taymaa","family":"May","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON M5G 1A1, Canada"},{"name":"Division of Gynecologic Oncology, Princess Margaret Cancer Center, Toronto, ON M5G 2C1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-1937","authenticated-orcid":false,"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Department of Obstetrics and Gynecology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"Canadian Cancer Society\u2019s Steering Committee on Cancer Statistics (2020). Soft Tissue Sarcoma Statistics, Canadian Cancer Society. Available online: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/ovarian\/statistics\/?region=on."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"National Cancer Institute, Cancer Treatment (2020, August 08). Biologicol Therapies for Cancer, Available online: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/bio-therapies-fact-sheet."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hirte, H., Yao, X., Ferguson, S.E., May, T., Elit, L., and The Ovarian Cancer guideline Development Group (2020). Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma, Ontario Health (Cancer Care Ontario). Program in Evidence-Based Care Guideline No.: 4\u201318.","DOI":"10.3390\/curroncol28020107"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2005.07.117","article-title":"Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study","volume":"100","author":"Alberts","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients with Advanced Ovarian Cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e31816060ce","article-title":"CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer","volume":"31","author":"Berek","year":"2008","journal-title":"J. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ijgc-00009577-200602001-00012","article-title":"Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: Results from a phase II study","volume":"16","author":"Bolis","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study","volume":"22","author":"Scambia","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"Floquet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"Kristensen","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2019.37.15_suppl.5512","article-title":"Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study","volume":"37","author":"Ferron","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","article-title":"Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters\u2014patient-centered end points in trials of maintenance therapy","volume":"29","author":"Friedlander","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.036","article-title":"Exploratory outcome analyses according to stage and\/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer","volume":"152","author":"Oza","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first-line treatment of patients with stage III\/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth","year":"2014","journal-title":"Cancer Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6602037","article-title":"Maintenance treatment with interferon for advanced ovarian cancer: Results of the Northern and Yorkshire gynaecology group randomised phase III study","volume":"91","author":"Hall","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","article-title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","volume":"130","author":"Herzog","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000602","article-title":"Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results from AGO-OVAR16 and an East Asian Study","volume":"28","author":"Kim","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","article-title":"Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg\/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial","volume":"114","author":"Markman","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III Randomized Trial of 12 versus 3 Months of Maintenance Paclitaxel in Patients with Advanced Ovarian Cancer after Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2012.04.050","article-title":"Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB\u2013IV","volume":"126","author":"Meier","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: A Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7150\/ijms.1.116","article-title":"A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?","volume":"1","author":"Nicoletto","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","article-title":"Phase III Trial of Observation versus Six Courses of Paclitaxel in Patients with Advanced Epithelial Ovarian Cancer in Complete Response after Six Courses of Paclitaxel\/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1","volume":"27","author":"Pecorelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 Trial of Bevacizumab in Ovarian Cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ijgc-00009577-200311001-00012","article-title":"Intraperitoneal cisplatin versus no further treatment: 8-Year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy","volume":"13","author":"Piccart","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Cibula","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as Maintenance Therapy in Patients with Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO\u2014The MIMOSA Study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","volume":"50","author":"Onstenk","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","article-title":"Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer","volume":"155","author":"Vergote","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): A randomised, double-blind, phase 3 trial","volume":"20","author":"Vergote","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2012.44.9116","article-title":"Randomized, Phase II, Placebo-Controlled, Double-Blind Study with and without Enzastaurin in Combination with Paclitaxel and Carboplatin as First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2013.50.5669","article-title":"Randomized Phase III Study of Erlotinib versus Observation in Patients with No Evidence of Disease Progression after First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study","volume":"32","author":"Vergote","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_45","unstructured":"Sch\u00fcnemann, H., Brozek, J., Guyatt, G., and Oxman, A.D. (2020, September 05). Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. Available online: http:\/\/gradepro.org."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:31:08Z","timestamp":1760160668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["curroncol28020107"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28020107","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}